[A20-19] Asfotase alfa (hypophosphatasia) - Addendum to Commission A19-89
Last updated 02.05.2020
Project no.:
A20-19
Commission:
Commission awarded on 24.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Indication:
Long-term enzyme replacement therapy in paediatric-onset hypophosphatasia to treat the bone manifestations of the disease
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-89 | Asfotase alfa (hypophosphatasia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.